News

The Phase III programme is being performed in conjunction with GW Pharma’s licensing partner for Sativex in the US, Otsuka Pharmaceutical. The programme, which is fully funded by

MIM-D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye that is responsible for the maintenance of corneal nerves and epithelium, mucin and

Epanova is an Omega 3 fatty acid containing a new formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omthera Pharma said that the multi-center, placebo-controlled, randomised, double-blind,

Generally, all Canadian drug establishments must hold an EL to manufacture, package, or conduct testing of pharmaceutical products. A5 Labs president and CEO Richard Azani said that in

Winston’s trial showed that, in the 210 patient Phase II double-blind, vehicle-controlled, multi-center study on patients with more than 180 headache days per year, twice-daily administration of Dolorac

Basilea Pharma claims that BAL30072 has broad antimicrobial activity against multidrug-resistant Gram-negative ‘superbugs’ that are increasingly associated with potentially life- threatening infections in hospitals around the world. Additionally,

Evotec will provide drug discovery expertise covering in-vitro biology, medicinal chemistry and in-vitro and in-vivo pharmacology. As part of the collaboration, Evotec will apply their integrated drug discovery

Profil Institute for Clinical Research Cardiometabolic Research director Robert Schott said that assessing cardiac safety is a critical early objective for the evaluation of new drugs, particularly in

Flutiform HFA-MDI is said to be a fixed-dose combination of fluticasone and formoterol in a metered dose inhaler (MDI). SkyePharma said that the two Phase III trials will